| HOME >> MEDICINE >> TECHNOLOGY |
SOUTH EASTON, Mass., Nov. 26, 2012 /PRNewswire/ -- Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company") and Constant Systems Ltd ("CS") today announced they have entered into a two-way, strategic marketing, selling, and distribution agreement (the "Agreement"). Under the terms of the Agreement, PBI has been awarded non-exclusive rights to market, sell, and distribute CS's unique, high-pressure cell disruption equipment and consumables in the United States, Canada, and Mexico. Concomitantly, CS has been awarded the rights to market, sell, and distribute PBI's patented pressure cycling technology ("PCT") based instruments and consumables in England, Scotland, Wales, Ireland, Spain, Portugal, Italy, Norway, Sweden, Finland, Denmark, and Singapore. CS currently has strong sales and distribution channels in all twelve of these countries; PBI, on the other hand, has none. The Agreement is in effect until December 31, 2013; however, PBI and CS expect to extend the Agreement prior to its termination.
Mr. Richard Mallabar, CEO of UK-based Constant Systems, said: "to date, throughout our sales network we have successfully installed close to 900 of our cell disruption units into more than 40 countries worldwide. To help us continue this trend of successful selling, and to increase our market share in North America, we have partnered with PBI. Their reputation, experience, and expertise in high pressure, market knowledge, installed base of over 200 PCT instruments in approximately 150 N. American labs, and their U.S. location, gives us confidence that together we will be highly successful in placing multiple cell disruption instruments in the U.S., Canada, and Mexico."
The initial Agreement focuses on cooperative marketing, selling, and distribution. The companies expect to co-market their products through shared booths at trade shows, joint email campaigns, combined advertisements and webcasts, and other m
'/>"/>
| SOURCE Pressure BioSciences, Inc. Copyright©2012 PR Newswire. All rights reserved |